Background. There are limited options available for the treatment of infections caused by Enterobacteriaceae that produce an NDM metallo-β-lactamase. The purpose of this study was to compare the in vitro activity of aztreonam in combination with three different β-lactam/β-lactamase inhibitors (ceftazidime-avibactam, amoxicillin-clavulanate, piperacillin-tazobactam) vs. NDM-positive Enterobacteriaceae clinical isolates.
Methods. Seven Escherichia coli and three Klebsiella pneumoniae clinical isolates (all NDM-positive by PCR) were included in this study. The in vitro activities of ceftazidime-avibactam, amoxicillin-clavulanate, piperacillin-tazobactam, and aztreonam were determined by disk diffusion as described by CLSI. For synergy testing, disks containing a β-lactamase inhibitor (ceftazidime-avibactam, amoxicillin-clavulanate, piperacillin tazobactam) were applied to Mueller-Hinton agar plates inoculated with the test organisms, and the plates were incubated for 1 hour. The disks were then removed and aztreonam disks were dropped on the previous disk sites. The plates were then incubated as per standard CLSI recommendations for disk diffusion testing.
Results.
All ten isolates demonstrated phenotypic resistance to aztreonam, amoxicillin-clavulanate, and piperacillin-tazobactam, and eight were resistant to ceftazidime-avibactam (CLSI breakpoints). The zone diameter observed for aztreonam in combination with ceftazidime-avibactam was greater than for either antimicrobial on its own for nine isolates. Seven isolates (70%) had susceptibility to aztreonam restored (zone diameter ≥21 mm) in the presence of avibactam. Aztreonam in combination with amoxicillin-clavulanate demonstrated in increase in zone diameter for all isolates relative to the zone for each antimicrobial alone, but only two (20%) had aztreonam susceptibility restored. Aztreonam susceptibility was not restored for any of the isolates in combination with piperacillin-tazobactam.
Conclusion. Of the three β-lactam/β-lactamase inhibitor-aztreonam combinations evaluated, ceftazidime-avibactam plus aztreonam demonstrated the greatest in vitro activity vs. NDM-producing Enterobacteriaceae.
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